The second-generation sulfonylureas glipizide (Glucotrol), glimepiride (Amaryl), and glyburide (
DiaBeta, Glynase, and Micronase) are prescribed much more frequently than the first-generation agents because they do not cause animal developmental toxicity, and can be considered low risk.
The second-generation sulfonylureas glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (
DiaBeta, Glynase, and Micronase) are prescribed much more frequently in pregnancy than the first-generation agents because they do not cause animal developmental toxicity, and can be considered low risk.
Second-generation agents in the sulfonylurea class include Glipizide (Glucotrol and Glucotrol XL) and Glyburide (Micronase, Glynase, and
Diabeta) and have been the standards for many years.
Starlix and a similar product called Prandin might have a unique use, i.e., for failure of other antidiabetic drugs, such as Micronase/Glynase,
Diabeta or Glucotrol, when their maximal doses are reached and fasting glucose is no longer reduced appropriately.
Diabetes Medications chlorpropamide (Diabenese) Treat type 2 diabetes by glipizide (Glucotol, Glucotrol XL) helping the pancreas glyburide (
DiaBeta, Glynase, Micronase) release insulin into the blood stream.
Other names for this medicine Generic name Brand name acetohexamide Dymelor chlorpropamide Diabinese glimepiride Amaryl glipizide Glucotrol, Glucotrol XL glyburide
DiaBeta, Glynase, PresTab, Micronase tolazamide Tolinase tolbutamide Orinase
TYPES AND NAMES OF DIABETES MEDICATIONS* CLASS BRAND NAMES Biguanides Glucophage, Fortamet GLP-1 receptor agonists Trulicity, Tanzeum, Bydureon, Victoza DPP-IV inhibitors Januvia, Onglyza, Nesina SGLT-2 inhibitors Invokana, Farxiga, Jardiance Sulfonylureas Amaryl, Glucotrol,
DiaBeta, Glynase Insulin Tresiba, Toujeo, Afrezza, Levemir, Lantus Combination drugs Janumet, Jentadueto, Kombiglyze, Tradjenta, Kazano, Oseni * This chart provides examples of some, but not all, medications used to treat diabetes.
(18.)
Diabeta [package insert],Bridgewater, NJ: sanofi-aventis; 2016.